ATE549017T1 - Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen - Google Patents

Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen

Info

Publication number: ATE549017T1
Authority: AT; Austria
Prior art keywords: tranilast; derivatives; neurological conditions; treatment; neuronal
Prior art date: 2007-08-17

Application number

AT08787273T

Other languages

English (en)

Inventor

Armin Schneider

Anja Moraru

Carola Krueger

Rico Laage

Claudia Pitzer

Original Assignee

Sygnis Bioscience Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-17

Filing date

2008-08-15

Publication date

2012-03-15

2008-08-15 Application filed by Sygnis Bioscience Gmbh & Co Kg filed Critical Sygnis Bioscience Gmbh & Co Kg

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE549017T1 publication Critical patent/ATE549017T1/de

Links

NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 title abstract 3
229960005342 tranilast Drugs 0.000 title abstract 3
230000000926 neurological effect Effects 0.000 title abstract 2
230000001537 neural effect Effects 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000004112 neuroprotection Effects 0.000 abstract 1
230000035771 neuroregeneration Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000000130 stem cell Anatomy 0.000 abstract 1
238000009168 stem cell therapy Methods 0.000 abstract 1
238000009580 stem-cell therapy Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT08787273T 2007-08-17 2008-08-15 Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen ATE549017T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07016189A EP2030617A1 (de)	2007-08-17	2007-08-17	Verwendungen von Tranilast und Derivaten daraus zur Behandlung neurologischer Leiden
PCT/EP2008/060745 WO2009024543A1 (en)	2007-08-17	2008-08-15	Use of tranilast and derivatives thereof for the therapy of neurological conditions

Publications (1)

Publication Number	Publication Date
ATE549017T1 true ATE549017T1 (de)	2012-03-15

Family

ID=38645596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08787273T ATE549017T1 (de)	2007-08-17	2008-08-15	Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen

Country Status (6)

Country	Link
US (1)	US20110112187A1 (de)
EP (2)	EP2030617A1 (de)
AT (1)	ATE549017T1 (de)
AU (1)	AU2008290583A1 (de)
CA (1)	CA2696582A1 (de)
WO (1)	WO2009024543A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX352516B (es) *	2006-07-05	2017-04-06	Fibrotech Therapeutics Pty Ltd	Compuestos terapeuticos.
CA2709937C (en) *	2007-12-21	2016-03-22	Fibrotech Therapeutics Pty Ltd	Halogenated analogues of anti-fibrotic agents
CN102574843B (zh)	2009-10-22	2015-06-17	法博太科制药有限公司	抗纤维化剂的稠环类似物
IN2014DN09031A (de)	2012-03-30	2015-05-22	Nuformix Ltd
EP4039255B1 (de) *	2014-04-24	2025-10-15	Omoidesouzou Co. Ltd.	Amyloidfaserbildungsbegrenzer oder -hemmer
KR101733085B1 (ko)	2016-04-20	2017-05-08	전남대학교산학협력단	귀리 추출물 아베난쓰라마이드 c 또는 이의 유도체를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약제학적 조성물 및 건강기능식품
JP7185631B2 (ja)	2017-02-03	2022-12-07	サータセラピューティクスプロプライエタリーリミテッド	抗線維化化合物
WO2020050423A1 (ja)	2018-09-07	2020-03-12	株式会社ファルネックス	非ラメラ液晶形成脂質を含む外用剤
CN117679520A (zh) *	2022-09-09	2024-03-12	北京达尔文细胞生物科技有限公司	用于防治后遗症期面神经麻痹的药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE222759T1 (de) *	1996-02-07	2002-09-15	Lead Chem Co Ltd	Tranilast enthaltendes externum und verfahren zu dessen herstellung
EP1601380A1 (de) *	2003-02-13	2005-12-07	Licentia OY	Verwendung eines mastzellen-aktivierenden oder degranulationshemmenden mittels bei der herstellung eines medikaments zur behandlung von zerebralischämie
US20100041756A1 (en) *	2004-11-17	2010-02-18	Michael Lionel Selley	method of modulating b cell functioning
JP2008526983A (ja) *	2005-01-14	2008-07-24	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	Ｔ細胞の機能性を調節する方法
BRPI0610349A2 (pt) *	2005-05-16	2010-06-15	Angiogen Pharmaceuticals Pty L	processos e composições para o tratamento de dor

2007
- 2007-08-17 EP EP07016189A patent/EP2030617A1/de not_active Withdrawn
2008
- 2008-08-15 AU AU2008290583A patent/AU2008290583A1/en not_active Abandoned
- 2008-08-15 US US12/673,943 patent/US20110112187A1/en not_active Abandoned
- 2008-08-15 WO PCT/EP2008/060745 patent/WO2009024543A1/en not_active Ceased
- 2008-08-15 EP EP08787273A patent/EP2185150B1/de not_active Not-in-force
- 2008-08-15 AT AT08787273T patent/ATE549017T1/de active
- 2008-08-15 CA CA2696582A patent/CA2696582A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2185150B1 (de)	2012-03-14
WO2009024543A1 (en)	2009-02-26
EP2185150A1 (de)	2010-05-19
EP2030617A1 (de)	2009-03-04
CA2696582A1 (en)	2009-02-26
US20110112187A1 (en)	2011-05-12
AU2008290583A1 (en)	2009-02-26

Similar Documents

Publication	Publication Date	Title
ATE549017T1 (de)	2012-03-15	Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen
ATE551063T1 (de)	2012-04-15	Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
EA201100440A1 (ru)	2011-10-31	Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
WO2009011871A3 (en)	2009-04-30	Thiadiazole modulators of pkb
MY155961A (en)	2015-12-31	Chemical compounds 251
MY148985A (en)	2013-06-28	2-aminopyridine analogs as glucokinase activators
WO2008046003A3 (en)	2008-08-21	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL211592A0 (en)	2011-05-31	Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
MY149143A (en)	2013-07-15	Thiazole compounds as protien kinase b (pkb) inhibitors
CR11383A (es)	2010-08-13	Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
WO2009011880A3 (en)	2009-04-02	Heterocyclic modulators of pkb
EA200802118A1 (ru)	2009-04-28	Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0810942A2 (pt)	2019-09-24	método para tratar, previnir, retardar o início ou o desenvolvimento de uma condição, método para promover a diferenciação ou proliferação de uma célula, método para estimular o crescimento de neuritos ou para intensificar a neurogênese num indivíduo, método para auxiliar no tratamento de um indivíduo, método para diferenciar células-tronco multipotenciais, composição farmacêutica, e kit.
ATE521608T1 (de)	2011-09-15	Glucokinaseaktivatoren
DE602006007093D1 (de)	2009-07-16	Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
BRPI0815715A8 (pt)	2017-07-04	Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
ATE438404T1 (de)	2009-08-15	Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
MX2009005725A (es)	2009-08-24	Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2008156685A3 (en)	2009-03-05	Tendon stem cells
ATE501718T1 (de)	2011-04-15	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
EA200800011A1 (ru)	2008-06-30	Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
ATE460936T1 (de)	2010-04-15	Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden
TW200716091A (en)	2007-05-01	New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2013002208A (es)	2013-05-30	Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
IL206738A0 (en)	2010-12-30	Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same